Details of the Drug

General Information of Drug (ID: DMM9S51)

Drug Name

ELND-002

Synonyms

ELND-002 (oral, multiple sclerosis); Alpha-4 integrin antagonists (oral, autoimmune diseases), Elan; Alpha-4 integrin antagonists (oral, multiple sclerosis), Elan; ELND-002 (oral, multiple sclerosis), Elan

Indication

Disease Entry	ICD 11	Status	REF
Autoimmune diabetes	5A10	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D01CYT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4 (ITGA4)	TT4BT06	ITA4_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01318421) A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis. U.S. National Institutes of Health.
2	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.